Canagliflozin 100 and 300mg significantly lowered haemoglobin A1c ( HbA1c ) compared with placebo at week 26 ( -0.89 % , -1.03 % and -0.26 % ; p < 0.001 ) ; reductions with canagliflozin 100 and 300mg were maintained at week 52 ( -0.92 % and -1.03 % ) .